useful in developing guidance for health departments seeking to determine whether and how to implement syndromic surveillance.

James W. Buehler,* Ruth L. Berkelman,* David M. Hartley,† and Clarence J. Peters‡
*Emory University, Atlanta, Georgia, USA; †University of Maryland School of Medicine, Baltimore, Maryland, USA; and ‡University of Texas Medical Branch, Galveston, Texas, USA

References:

1. Sichel LS, Greenko J, Heffernan R, Weiss D. Field investigations of emergency department syndromic surveillance signals, New York City. Presentation at the 2003 National Syndromic Surveillance Conference [cited 2004 Jan]. Available from: http://www.syndromic.org/pdf/con2-LS-8b.pdf

2. Sosin DM. Syndromic surveillance: the case for skillful investment. Biosecur Bioterror. 2003;1:247–53.

3. Centers for Disease Control and Prevention. Global progress toward certifying polio eradication and laboratory containment of wild polioviruses, August 2002–August 2003. MMWR.2003;52:1158–60.

4. Centers for Disease Control and Prevention. Public health dispatch: update: fatal and severe liver injuries associated with rifampin and pyrazinamide treatment for latent tuberculosis infection. MMWR. 2003;52:998–9.

5. Tan CG, Sandhu HS, Crawford DC, Redd SC, Beach MJ, Buehler JW, et al. Surveillance for anthrax cases associated with contaminated letters, New Jersey, Delaware, and Pennsylvania, 2001. Emerg Infect Dis. 2002;8:1073–7.

6. UNAIDS/WHO Working Group on Global HIV/AIDS/STI Surveillance. Guidelines for sexually transmitted infections surveillance [monograph on the Internet]. 1999 [cited 2004 Jan]. Available from: http://www.who.int/emc-documents/STIs/docs/whocdscscr0993.pdf

7. Osterholm MT, Forfang JC. Toxic-shock syndrome in Minnesota: results of an active-passive surveillance system. J Infect Dis. 1982;145:458–64.

8. Centers for Disease Control and Prevention. Current trends update on acquired immune deficiency syndrome (AIDS)—United States. MMWR. 1982;31:507–8, 513–4.

9. Centers for Disease Control and Prevention. Outbreak of severe acute respiratory syndrome—worldwide, 2003. MMWR Morb Mortal Wkly Rep. 2003;53:226–8.

10. Centers for Disease Control and Prevention. Framework for evaluating public health surveillance systems for early detection of outbreaks; recommendations from the CDC working group. MMWR. 2004;53(No. RR-5):1–11.

Address for correspondence: James W. Buehler, Rollins School of Public Health, Rm. 416, Emory University, 1518 Clifton Rd., NE, Atlanta, GA 30322, USA; fax: 404-712-8345; email: jbuehler@sph.emory.edu

Staphylococcus aureus and Escherichia hermanii in Diabetes Patient

To the Editor: Polymicrobial invasive infections are infrequent, representing <10% of the invasive infections of known etiology (1). They are often correlated with a predisposing factor: immunodeficiency (e.g., diabetes mellitus, malignancies, extremes of age) or use of a central catheter. Escherichia hermanii is an extremely rare etiologic agent for invasive infections; only four cases were published from 1980 to 2002. We report the first case of double invasive infection by E. hermanii and Staphylococcus aureus and emphasize the importance of screening of all the septic foci for demonstrating a polymicrobial invasive infection.

In August 2000, a 54-year-old comatose man was admitted to our infectious diseases department with a 10-day history of fever. He had a medical history of vertebral arthrosis (lumbar laminectomy in 1989) and insulin-dependent diabetes mellitus. Six weeks before, he had received for 3 days gluteal injections with kebunone (an intramuscular nonsteriodal antiinflammatory drug [NSAID]) for acute lower back pain. Twenty-eight days after the first injection, a gluteal abscess developed, which was surgically drained, without perioperative antimicrobial therapy. Three days later, he became febrile, and pyrexia persisted despite local wound management and treatment with oxacillin, 4 g/day for 3 days; cefuroxime, 3 g/day; and gentamicin, 160 mg/day for another 7 days.

The patient became comatose and was transferred to our department. At that time, the physical examination showed fever (40.2°C), neck stiffness, Brudzinski sign, thoracic dullness, and bilateral crackling rales. The level of C-reactive protein was 123 mg/L. Renal failure was noted with a creatinine blood level of 312 mmol/L and uncontrolled diabetes with fasting glucose of 24.75 mmol/L. Computed tomographic (CT) scan of the brain did not show brain abscesses or tumors. Examination of the cerebrospinal fluid (CSF) indicated a protein level of 2.67 g/L, decreased glucose concentration of 0.55 mmol/L, and a leukocyte count of 2.3 x 10³/L with 96% neutrophils; no microbial pathogens were demonstrable under direct examination of CSF. Chest x-ray identified bronchopneumonia and bilateral pleural effusion. The pleural fluid analysis revealed a purulent exudate—protein, 4.5 g/L—containing 55% neutrophils. A urine specimen and three blood samples were obtained for cultures over the first 4 hours after admission. A bacterial invasive infection was considered and the antibiotic therapy was started with ceftriaxone, 2 g/day, and rifampin, 1,200 mg/day. Concomitantly, the patient received colloids to reestablish blood volume, intravenous dexamethasone, 6 mg four times daily, to diminish the cerebral edema; and fast-
acting insulin to control hyperglycemia.

On day 3, the urine and CSF cultures were positive for *E. hermanii*, and the pleural fluid and all three blood cultures yielded methicillin-susceptible *S. aureus*. The *E. hermanii* strain produced a yellow pigment. The drug susceptibility was assessed by AtB Expression system (BioMerieux, Marcy l’Etoile, France). The *Staphylococcus* strain was susceptible to oxacillin, cotrimoxazole, tetracycline, and ciprofloxacin and resistant only to penicillin. *E. hermanii* is naturally resistant to aminopenicillins and carbencillin; this strain was susceptible to third-generation cephalosporins, carbapenems, cotrimoxazole, and quinolones and resistant to aminoglycosides.

The patient’s clinical central nervous system status improved, and he came out of the coma, but his temperature remained >37.5°C. He started to report lumbar pain. On day 5, the antimicrobial regimen was switched to meropenem. After 24 hours, the patient became afebrile, and glucose and creatinine levels were normal on day 8. However, on day 10, fever, inflammation of the right thumb, and intensified lower back pain developed. The abdominal CT and bone scintigraphy indicated absence of the psoas, L4-L5 spondylitis, and thumb periostitis. Intravenous ciprofloxacin was added, 400 mg twice daily, and apyrexia occurred on day 14. On day 21, open surgery was performed, consisting of drainage of the psoas abscess and curettage of the L4-L5 disc. On day 30, clinical improvement and C-reactive protein level of 4.2 mg/L, led to a change to oral antimicrobial agents: cotrimoxazole 2 g/day and ciprofloxacin 1.5 g/day. This regimen was continued for 2 months while the patient was seen as an outpatient. The patient remained afebrile and inflammation-free for the entire 24-month followup period.

Polymicrobial invasive infections represent a major therapeutic problem. However, they are infrequent: only 3.2% of infectious endocarditis (2) cases and 6.27% of 2,188 community-acquired bacteremia cases (3) were polymicrobial. Polymicrobial infections and elevated bacteremia levels are more frequently associated with diabetes; 20%–35% of the skin and soft tissue infections in persons with diabetes are polymicrobial (4), and 15.7%–20% of the community-acquired bacteremia cases were registered in persons with diabetes (3,4). The probable entry site for *S. aureus* was cutaneous. Intramuscular NSAIDs are known to cause aseptic necrosis, predisposing the patient to staphylococcal abscesses. Hyperglycemia itself is a risk factor for soft-tissue infections. The role of perioperative antimicrobial therapy in preventing the dissemination of infection from a surgically drained abscess is controversial (5). *E. hermanii* usually produces wound or gastrointestinal tract infections; in our patient, *E. hermanii* probably originated from the skin or from the gastrointestinal tract (6–9). *E. hermanii* could be involved more frequently in polymicrobial invasive infections; of *E. hermanii* invasive infections noted in four published reports, two were polymicrobial (6,7).

Initial antimicrobial drug therapy was established empirically for probable staphylococcal meningitis. The ongoing fever and persistent metabolic disturbances led to an escalation of therapy. Some authors recommend carbapenems as the initial regimen against invasive methicillin-susceptible *S. aureus* infections with meningitis or bone involvement (10). The patient’s lower back and the invasive staphylococcal infection urged us to consider septic bone involvement. The imaging studies confirmed the existence of vertebral osteomyelitis; ciprofloxacin was used based on its excellent bone diffusion and its in vitro activity on the two isolated strains. Surgical intervention eradicated one of the septic foci and decreased risk for spinal cord injury; 27 (47%) of the 58 patients with spondylodiscitis who were treated surgically had a better outcome than the other patients with medical care only (11). Control of the infection allowed changing to an oral regimen after 1 month. We selected cotrimoxazole and ciprofloxacin for their in vitro effectiveness against the two pathogens. Although this agent is not usually used to treat bone infection, we used cotrimoxazole on the basis of evidence provided by several communications that indicated a superior efficiency to referential regimens (12).

In conclusion, the identification of all organisms involved in polymicrobial invasive infections may require cultures of specimens from all accessible septic foci. For *E. hermanii*, a role of “associated” pathogen in a polymicrobial invasive infection could be considered. Medical therapy alone could be insufficient, and the combined therapy allowed for a successful outcome in invasive infection with lumbar spondylodiscitis.

Gabriel Adrian Popescu,*‡ Ioana Daha,†‡ Cristina Popescu,*‡ and Elena Mitache∗

*Matei Bals Infectious Diseases Institute, Bucharest, Romania; †Colentina Hospital, Bucharest, Romania; and ‡Carol Davila University of Medicine, Bucharest, Romania

References
1. Ruiz-Giardin JM, Nogueredo A, Pizarro A, Mendez J, La Hulla F, Fernandez M, et al. Comparative study of prognostic and risk factors for mortality in polymicrobial bacteremia-fungemia in a university hospital: development over 10 years. Enferm Infec Microbiol Clin. 2002;20:435–42.
2. Cicalini S, Francavilla R, Massaroni K, De Rosa FG. Polymicrobial infective endocarditis in Italy. Recenti Prog Med.
Multiple rpoB Mutants of Mycobacterium tuberculosis and Second-order Selection

To the Editor: Rad and colleagues recently described variation in some genes involved in DNA repair (mutT2, mutT4, ogt) in Mycobacterium tuberculosis strains of different genotypes (1). This approach can also be used to investigate developing rifampin resistance in the context of emerging mutator alleles. Resistance to rifampin in M. tuberculosis strains is usually caused by the point mutations in the rpoB gene encoding the β-subunit of the DNA-dependent RNA polymerase, which is a target of the drug. Although a single point mutation is sufficient for developing rifampin resistance, a number of articles (2,3) describe multiple rpoB mutants for M. tuberculosis, i.e., rifampin-resistant strains harboring mutations in different codons of rpoB. Double, triple, and quadruple mutations in M. tuberculosis clinical isolates were reported in studies conducted throughout the world (2,3). Such emergence, albeit infrequent, of M. tuberculosis rpoB multiple mutants raises questions about their biologic importance and underlying mechanisms; answers to both remain elusive.

I propose an explanation of these observations in terms of second-order selection of hypermutable (mutator) alleles based on alterations in DNA repair genes. Unlike that of other antituberculosis drugs, resistance to rifampin is acquired in most M. tuberculosis isolates by altering a single target molecule and offers the most appropriate and straightforward model to demonstrate possible hypermutability in this species. In mycobacteria, hypermutability was demonstrated in vitro for M. smegmatis, a surrogate model for M. tuberculosis, as an increase in reversion (mutant to wild-type) rate in rpoB526 or rpsL43 under counterselection by streptomycin or rifampin, respectively (4). A correlation between high mutation rate and antimicrobial resistance was reported for Pseudomonas aeruginosa isolates from lungs of cystic fibrosis patients (5). The mutator P. aeruginosa strains resulted from a defective mismatch-repair system (5). In M. tuberculosis, mismatch-repair genes (mutH, mutL, mutS, and recJ) were not found in its genome (6). However, the nucleotide pool in this species is exceptionally clean because of the presence of several copies of the mutT gene (1,6); the MutT protein removes oxidized guanines (8-OxodGTP), thus counteracting replication or transcription errors. Consequently, the MutHLS mismatch-repair system simply may be not required in M. tuberculosis (6). Therefore, hypermutability in some strains of this species resulting in multiple rpoB mutants might develop under certain special (in vivo) circumstances through inactivation or down-regulation of some mutT genes. Further, the two most frequently described rpoB mutations are 531TCG→TTG and 526CAC→TAC. Both are cytosine-to-tymine transitions, which easily occur by spontaneous cytosine deamination to uracil. Indeed, M. tuberculosis is a G+C rich organism, therefore, it is naturally at high risk for cytosine deamination. Furthermore, pathogenic mycobacteria are at increased risk for deamination because of the production of reactive oxygen and nitrogen intermediates inside host macrophages. This deamination process is normally counteracted by uracil-N-glycosylase, the product of the ung gene, and organisms defective in the removal of uracil from DNA have an increased spontaneous mutation rate and more G:C→A:T base-pair transitions (7).